INNO:CA:CNSX-InnoCan Pharma Corporation (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.19

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

0.12M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.77 (-6.66%)

USD 2.72B
TRUL:CA Trulieve Cannabis Corp

-0.24 (-3.19%)

USD 1.31B
CL:CA Cresco Labs Inc

-0.09 (-6.12%)

USD 0.41B
GRIN:CA Grown Rogue International Inc

-0.01 (-1.10%)

USD 0.20B
PLTH:CA Planet 13 Holdings Inc

-0.01 (-1.85%)

USD 0.17B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.04 (-8.70%)

USD 0.09B
JUSH:CA Jushi Holdings Inc

-0.01 (-1.16%)

USD 0.08B
MRMD:CA MariMed Inc.

+0.01 (+3.13%)

USD 0.07B
AYR-A:CA Ayr Wellness Inc

-0.07 (-9.46%)

USD 0.07B
LEEF:CA Leef Brands Inc.

N/A

USD 0.05B

ETFs Containing INNO:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.52% 21% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.52% 21% F 23% F
Trailing 12 Months  
Capital Gain -40.63% 48% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.63% 48% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.45% 44% F 33% F
Dividend Return -13.45% 44% F 33% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.21% 79% B- 68% D+
Risk Adjusted Return -43.09% 30% F 27% F
Market Capitalization 0.06B 86% B+ 96% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector